Merck & Co. (MRK) Q3 2024 Earnings
MRK·Reported October 31, 2024·Before market open
Merck & Co. reported Q3 2024 revenue of $16.7B, beat analyst consensus of $16.5B by $183.3M. Diluted EPS came in at $1.57, beat the $1.50 consensus by $0.07. Merck & Co. reports across 2 business segments, led by Pharmaceutical and Animal Health.
Revenue
$16.7Bbeat by $183.3M
Consensus: $16.5BDiluted EPS
$1.57beat by $0.07
Consensus: $1.50
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Merck & Co.'s Q3 2024 earnings report.
Merck & Co. (MRK) reported Q3 2024 earnings on October 31, 2024 before market open.
Merck & Co. reported revenue of $16.7B and diluted EPS of $1.57 for Q3 2024.
Revenue beat the consensus estimate of $16.5B by $183.3M. EPS beat the consensus estimate of $1.50 by $0.07.
You can read the 10-Q periodic report (0001628280-24-045689) directly on SEC EDGAR. The filing index links above go to sec.gov.